Related Experiment Video

Updated: Jul 5, 2025

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.0K

Development of PARP inhibitors in advanced prostate cancer

Maria Teresa Bourlon1, Paola Valdez1, Elena Castro2

  • 1Hemato-Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

Therapeutic Advances in Medical Oncology
|January 11, 2024
PubMed

Insights

Poly ADP-ribose polymerase (PARP) inhibitors show promise for advanced prostate cancer. Research explores combining PARP inhibitors with other therapies to benefit more patients with DNA repair defects.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Advanced prostate cancer often features homologous recombination repair (HRR) pathway alterations, creating vulnerabilities.
  • Poly ADP-ribose polymerase (PARP) inhibitors (PARPi) improve outcomes in metastatic castration-resistant prostate cancer (mCRPC) with HRR defects, especially BRCA1/2 alterations.

Purpose of the Study:

  • To review the development and therapeutic potential of PARP inhibitors in prostate cancer.
  • To explore novel synergistic combinations and future directions for PARPi in prostate cancer management.

Main Methods:

  • Review of current literature on PARP inhibitors in prostate cancer.
  • Analysis of ongoing clinical trials investigating PARPi combinations.

Main Results:

  • PARPi are effective in mCRPC patients with HRR defects, particularly BRCA1/2 alterations.
  • Investigating synergies between PARPi and androgen receptor pathway inhibitors, radiation, radioligand therapy, chemotherapy, and immunotherapy.

Conclusions:

  • Expanding PARPi benefit to patients without detectable HRR alterations is a key research focus.
  • Combination strategies and evaluation in hormone-sensitive settings represent future directions for PARPi in prostate cancer.
Keywords:
BRCAHRRPARP inhibitionnirapribolaparibprostate cancerrucaparibtalazoparib

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K